PTC Therapeutics shares are trading lower after the company announced results from a two-year interim analysis of the PIVOT-HD long-term extension study of votoplam for Stage 2 Huntington's disease.

Benzinga Newsdesk www.benzinga.com Negative 96.7%

Neg 96.7% Neu 0% Pos 0%

Comments

No comments yet. Be the first!